Qualigen Therapeutics, Inc.
QLGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $106 | $18 | $33 | -$45 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,324 | $1,666 | $2,692 | $1,378 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,430 | $1,684 | $2,725 | $1,333 |
| Operating Income | -$1,430 | -$1,684 | -$2,725 | -$1,333 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$608 | -$2 | $79 | $483 |
| Pre-Tax Income | -$2,038 | -$1,685 | -$2,646 | -$850 |
| Tax Expense | $0 | $0 | $0 | $6 |
| Net Income | -$2,038 | -$1,685 | -$2,646 | -$856 |
| % Margin | – | – | – | – |
| EPS | -1.73 | -1 | -1.82 | -0.19 |
| % Growth | -73% | 45.1% | -857.9% | – |
| EPS Diluted | -1.73 | -1 | -1.82 | -0.19 |
| Weighted Avg Shares Out | 1,684 | 1,684 | 1,456 | 4,530 |
| Weighted Avg Shares Out Dil | 1,684 | 1,684 | 1,456 | 4,530 |
| Supplemental Information | – | – | – | – |
| Interest Income | $194 | $142 | $113 | $81 |
| Interest Expense | $456 | $106 | $74 | $100 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1,582 | -$1,579 | -$2,573 | -$750 |
| % Margin | – | – | – | – |